Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APVO
stocks logo

APVO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.450
-99.75%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Aptevo Therapeutics Inc. (APVO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -13.66%.
EPS Estimates for FY2025
Revise Downward
down Image
-62.06%
In Past 3 Month
Stock Price
Go Down
down Image
-13.66%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Aptevo Therapeutics Inc (APVO.O) is -0.55, compared to its 5-year average forward P/E of -0.89. For a more detailed relative valuation and DCF analysis to assess Aptevo Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.89
Current PE
-0.55
Overvalued PE
1.45
Undervalued PE
-3.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.17
Current PS
0.00
Overvalued PS
9.68
Undervalued PS
-3.34
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

APVO News & Events

Events Timeline

(ET)
2025-11-10
09:12:30
Aptevo Therapeutics Launches Trispecific Antibody Candidate APVO451
select
2025-11-06 (ET)
2025-11-06
09:18:40
Aptevo Therapeutics projects funding to last until the fourth quarter of 2026.
select
2025-11-06
09:17:54
Aptevo Therapeutics announces Q3 EPS of $2.23 compared to a loss of $357.86 in the same period last year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
09-19Benzinga
Gold Declines by More Than 1%; Darden Reports Disappointing Earnings

  • U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow Jones up 0.37%, NASDAQ rising 1.07%, and S&P 500 increasing by 0.62%. Information technology shares led the rise, while materials stocks fell by 0.7%.

  • Darden Restaurants Financial Results: Darden Restaurants reported disappointing first-quarter earnings of $1.97 per share, missing the expected $2.00, and quarterly sales of $3.004 billion, below the $3.040 billion estimate.

  • Notable Stock Movements: 89bio, Inc. shares surged 86% after an acquisition announcement, while Intel Corporation's stock rose 27% following a partnership with NVIDIA. Conversely, Replimune Group, Inc. shares dropped 39% due to FDA feedback evaluation.

  • Economic Indicators: U.S. initial jobless claims fell to 231,000, lower than expected, and the Philadelphia Fed Manufacturing Index rose to +23.2, marking its highest level since January.

[object Object]
Preview
9.5
09-19TipRanks
Thursday's Major Stock Market Highlights: Morning News Summary!

  • Earnings Reports: Key earnings reports are being released, impacting stock market movements and investor sentiment.

  • Legal and Investment News: Lawsuits and new investments are also significant factors influencing the stock market landscape today.

[object Object]
Preview
4.5
09-18Benzinga
Nasdaq Rises by 100 Points as US Initial Jobless Claims Decrease

  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite gaining over 100 points, while the Dow dipped slightly. The S&P 500 also saw a modest increase, and information technology shares rose by 0.8%.

  • Jobless Claims and Economic Indicators: Initial jobless claims in the U.S. fell by 33,000 to 231,000, better than market expectations. Additionally, the Philadelphia Fed Manufacturing Index improved significantly, reaching +23.2 in September.

  • Notable Stock Movements: 89bio, Inc. and Aeries Technology, Inc. both surged by 85% following acquisition and partnership announcements, respectively. Conversely, Replimune Group, Inc. and BioCardia, Inc. experienced significant declines of 40% and 34%, respectively.

  • Global Market Trends: European shares generally rose, with the eurozone's STOXX 600 up by 0.8%. In Asia, markets closed mixed, with Japan's Nikkei gaining while Hong Kong's Hang Seng and China's Shanghai Composite fell.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aptevo Therapeutics Inc (APVO) stock price today?

The current price of APVO is 1.39 USD — it has increased 0.72 % in the last trading day.

arrow icon

What is Aptevo Therapeutics Inc (APVO)'s business?

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

arrow icon

What is the price predicton of APVO Stock?

Wall Street analysts forecast APVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APVO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aptevo Therapeutics Inc (APVO)'s revenue for the last quarter?

Aptevo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Aptevo Therapeutics Inc (APVO)'s earnings per share (EPS) for the last quarter?

Aptevo Therapeutics Inc. EPS for the last quarter amounts to -2.23 USD, decreased -99.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aptevo Therapeutics Inc (APVO)'s fundamentals?

The market is revising No Change the revenue expectations for Aptevo Therapeutics Inc. (APVO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -13.66%.
arrow icon

How many employees does Aptevo Therapeutics Inc (APVO). have?

Aptevo Therapeutics Inc (APVO) has 37 emplpoyees as of December 05 2025.

arrow icon

What is Aptevo Therapeutics Inc (APVO) market cap?

Today APVO has the market capitalization of 23.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free